Citation Report
List of articles citing

Empagliflozin Ammeliorates High Glucose Induced-Cardiac Dysfuntion in Human iPSC-Derived Cardio

DOI: 10.1038/s41598-018-33293-2
Scientific Reports, 2018, 8, 14872.

#	Paper	IF	Citations
42	Empagliflozin prevents cardiomyopathy via sGC-cGMP-PKG pathway in type 2 diabetes mice. *Clinical Science*, **2019**, 133, 1705-1720	6.5	34
41	Human Induced Pluripotent Stem-Cell-Derived Cardiomyocytes as Models for Genetic Cardiomyopathies. *International Journal of Molecular Sciences*, **2019**, 20,	6.3	26
40	Further insights into cardiovascular outcomes in diabetic and non-diabetic states: inhibition of sodium-glucose co-transports. *Cardiovascular Endocrinology and Metabolism*, **2019**, 8, 90-95	2.5	
39	Cardioprotective Effects of Sirtuin-1 and Its Downstream Effectors: Potential Role in Mediating the Heart Failure Benefits of SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitors. *Circulation: Heart Failure*, **2020**, 13, e007197	7.6	33
38	Empagliflozin prevents doxorubicin-induced myocardial dysfunction. *Cardiovascular Diabetology*, **2020**, 19, 66	8.7	20
37	Beyond Family: Modeling Non-hereditary Heart Diseases With Human Pluripotent Stem Cell-Derived Cardiomyocytes. *Frontiers in Physiology*, **2020**, 11, 384	4.6	1
36	Changes in Myocardial Metabolism Preceding Sudden Cardiac Death. *Frontiers in Physiology*, **2020**, 11, 640	4.6	1
35	Intensive care for human hearts in pluripotent stem cell models. *Npj Regenerative Medicine*, **2020**, 5, 4	15.8	5
34	Patient and Disease-Specific Induced Pluripotent Stem Cells for Discovery of Personalized Cardiovascular Drugs and Therapeutics. *Pharmacological Reviews*, **2020**, 72, 320-342	22.5	67
33	Effect of hyperglycaemia and diabetes on acute myocardial ischaemia-reperfusion injury and cardioprotection by ischaemic conditioning protocols. *British Journal of Pharmacology*, **2020**, 177, 5312-5335	8.6	40
32	Sodium-glucose cotransporter 2 inhibition: towards an indication to treat diabetic kidney disease. *Nephrology Dialysis Transplantation*, **2020**, 35, i13-i23	4.3	13
31	Effects of extreme potassium stress on blood pressure and renal tubular sodium transport. *American Journal of Physiology - Renal Physiology*, **2020**, 318, F1341-F1356	4.3	6
30	Human-induced pluripotent stem cells for modelling metabolic perturbations and impaired bioenergetics underlying cardiomyopathies. *Cardiovascular Research*, **2021**, 117, 694-711	9.9	4
29	Sodium-glucose co-transporter 2 inhibitor therapy: mechanisms of action in heart failure. *Heart*, **2021**,	5.1	36
28	Human induced pluripotent stem cell (iPSC)-derived cardiomyocytes as an in vitro model in toxicology: strengths and weaknesses for hazard identification and risk characterization. *Expert Opinion on Drug Metabolism and Toxicology*, **2021**, 17, 887-902	5.5	6
27	Maturation of Pluripotent Stem Cell-Derived Cardiomyocytes Enables Modeling of Human Hypertrophic Cardiomyopathy. *Stem Cell Reports*, **2021**, 16, 519-533	8	12
26	Effects of canagliflozin on human myocardial redox signalling: clinical implications. *European Heart Journal*, **2021**,	9.5	14

25	The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin. *Cardiovascular Diabetology*, **2021**, 20, 150	8.7	27
24	Glucose fluctuation accelerates cardiac injury of diabetic mice via sodium-dependent glucose cotransporter 1 (SGLT1). *Archives of Biochemistry and Biophysics*, **2021**, 709, 108968	4.1	2
23	Environmental Alterations during Embryonic Development: Studying the Impact of Stressors on Pluripotent Stem Cell-Derived Cardiomyocytes. *Genes*, **2021**, 12,	4.2	1
22	The dawn of the four-drug era? SGLT2 inhibition in heart failure with reduced ejection fraction. *Therapeutic Advances in Cardiovascular Disease*, **2021**, 15, 17539447211002678	3.4	3
21	Maturation of human induced pluripotent stem cell-derived cardiomyocytes for modeling hypertrophic cardiomyopathy.		0
20	Mechanisms underlying diabetic cardiomyopathy: From pathophysiology to novel therapeutic targets. *Conditioning Medicine*, **2020**, 3, 82-97	1.4	2
19	Crosstalk between Sodium-Glucose Cotransporter Inhibitors and Sodium-Hydrogen Exchanger 1 and 3 in Cardiometabolic Diseases. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	1
18	Human Induced Pluripotent Stem Cell as a Disease Modeling and Drug Development Platform-A Cardiac Perspective.. *Cells*, **2021**, 10,	7.9	0
17	SGLT2 Inhibitors and Their Antiarrhythmic Properties.. *International Journal of Molecular Sciences*, **2022**, 23,	6.3	0
16	Targeting □Synuclein in Parkinson□Disease by Induced Pluripotent Stem Cell Models.. *Frontiers in Neurology*, **2021**, 12, 786835	4.1	0
15	Generating 3D human cardiac constructs from pluripotent stem cells.. *EBioMedicine*, **2022**, 76, 103813	8.8	4
14	Advances in Manufacturing Cardiomyocytes from Human Pluripotent Stem Cells.. *Annual Review of Chemical and Biomolecular Engineering*, **2022**,	8.9	
13	Pathophysiology and Treatment of Diabetic Cardiomyopathy and Heart Failure in Patients with Diabetes Mellitus.. *International Journal of Molecular Sciences*, **2022**, 23,	6.3	3
12	Cellular interplay between cardiomyocytes and non-myocytes in diabetic cardiomyopathy.. *Cardiovascular Research*, **2022**,	9.9	0
11	Data_Sheet_1.PDF. **2020**,		
10	Guidelines on Models of Diabetic Heart Disease. *American Journal of Physiology - Heart and Circulatory Physiology*,	5.2	1
9	SGLT2 Inhibitor Empagliflozin Modulates Ion Channels in Adult Zebrafish Heart. **2022**, 23, 9559		0
8	Sodium-glucose cotransporter-2 (SGLT2) expression in diabetic and non-diabetic failing human cardiomyocytes. **2022**, 184, 106448		0

7	Hepatic expression of sodium glucose cotransporter 2 (SGLT2) in patients with chronic liver disease.	0
6	Sodium Glucose cotransporter 2 inhibitor empagliflozin decreases ventricular arrhythmia susceptibility by alleviating electrophysiological remodeling post-myocardial-infarction in mice. 13,	0
5	Glucagon-Like Peptide-1 (GLP-1) Rescue Diabetic Cardiac Dysfuntions in Human iPSC-Derived Cardiomyocytes. 2200130	0
4	Empagliflozin activates JAK2/STAT3 signaling and protects cardiomyocytes from hypoxia/reoxygenation injury under high glucose conditions.	0
3	Targeting High Glucose-Induced Epigenetic Modifications at Cardiac Levels: The Role of SGLT2 and SGLT2 Inhibitors.	0
2	The Importance of SGLT-2 Inhibitors as Both the Prevention and the Treatment of Diabetic Cardiomyopathy. **2022**, 11, 2500	0
1	Emerging sodium-glucose cotransporter-2 inhibitor therapies for managing heart failure in patients with chronic kidney disease. 1-11	0